<DOC>
	<DOCNO>NCT01668121</DOCNO>
	<brief_summary>The primary objective study evaluate acceptance range two Symbicort Turbohaler batch could declare bioequivalent bioequivalence setting . The secondary objective compare pharmacokinetic parameter reference product batch Budesonide/formoterol Easyhaler .</brief_summary>
	<brief_title>Pharmacokinetic Study Budesonide/Formoterol Device-metered Dry Powder Inhalers</brief_title>
	<detailed_description />
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Written informed consent ( IC ) obtain . 2 . Males female , 1855 ( inclusive ) year age . 3 . Normal weight define body mass index ( BMI ) &gt; 19 &lt; 30 kg/m2 ( BMI= weight/height2 ) . 4 . Weight least 50 kg . 5 . Forced expiratory volume one second ( FEV1 ) least 80 % predict value measure screen . 6 . Good general health ascertain detailed medical history , laboratory physical examination . 1 . Vulnerable subject ( i.e . person administrative legal supervision ) . 2 . Evidence clinically significant cardiovascular , renal , hepatic , haematological , gastrointestinal , pulmonary , metabolicendocrine , neurological psychiatric disease within previous 2 year ; evidence active quiescent pulmonary tuberculosis , fungal viral infection airway . 3 . Any condition require regular concomitant treatment ( include vitamin herbal product ) likely need concomitant treatment study . As exception , paracetamol ibuprofen occasional pain allow . 4 . Intake medication could affect outcome study . As exception , contraceptives hormone replacement therapy allow . The use medicine strong CYP3A4 inducer inhibitor restrict least 2 week prior first study treatment administration study . 5 . Any clinically significant abnormal laboratory value physical finding ( include electrocardiogram [ ECG ] vital sign ) may interfere interpretation test result cause health risk subject he/she participates study , judge investigator . More specifically , supine HR &lt; 45 &gt; 100 bpm 10min rest supine systolic BP &gt; 140 &lt; 90 diastolic BP &gt; 90 &lt; 60 mmHg 10minute rest , QTcBazett ( QTcB interval ) &gt; 450 msec screen evaluation . 6 . Known hypersensitivity active substance excipient ( lactose , contain small amount milk protein ) drug . 7 . History vasovagal collapse . 8 . History anaphylactic/anaphylactoid reaction . 9 . History seizure include febrile seizure . 10 . Pregnant lactating female . 11 . Females childbearing potential use proper contraception ( mechanical and/or hormonal contraception , intrauterine device [ IUD ] surgical sterilization ) . Double method contraception need use oral mechanical contraception : e.g . condom conjunct oral contraception spermicidal product mechanical contraception ( please see section 5.7 detail ) . 12 . Recent current ( suspect ) drug abuse positive result drug abuse test . 13 . Recent current alcohol abuse ( regular drinking 21 unit per week male 16 unit per week female [ 1 unit = 4 cl spirit equivalent ] ) . 14 . Current use nicotine containing product 5 cigarette ( equivalent ) /day and/or inability refrain use nicotine containing product study ( screen visit endofstudy visit ) . 15 . Use caffeine containing beverage 600 mg caffeine/day and/or inability refrain use caffeine contain beverage treatment period 24 h study treatment administration . 16 . Blood donation loss significant amount blood within 30 day prior first study treatment administration . 17 . Administration another investigational drug within 30 day prior first study treatment administration . 18 . Unsuitable vein repeat venepuncture cannulation . 19 . Inability learn correct inhalation technique . 20 . Predictable poor compliance inability communicate well study centre personnel . 21 . Inability participate treatment period . 22 . The subject able understand comply protocol requirement , instruction protocolstated restriction . 23 . Positive result HIV , hepatitis B C test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>